Gene

ACOT11

acyl-CoA thioesterase 11

Explore in graph →CI-GENE-00000239HGNC:18156 ENSG00000162390 NCBI 26027 Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ACOT11 Fusion1
Erdafitinib	Intrahepatic Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID13163 In the phase II NCI-MATCH EAY131-K2 trial, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-ACOT11 fusion achieved a partial response to erdafitinib, with a 49.6% maximum reduction in… (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (3)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved3 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Germ Cell Tumors and Shared Leukemias (MSK, J Clin Invest 2020) gct_msk_2020	unmapped	Ssm	1	13	7.7%

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed